Most notable was the evidence that the SMAD3 gene, which encodes a key regulatory protein in the transforming growth factor beta signalling pathway, may contribute to increased risk of breast cancer in BRCA2 mutation carriers. This evidence concerns the gene SMAD3 and breast cancer.